Table 4. Microneutralization response: MF59-adjuvanted H5N1 subunit influenza vaccine formulations and age cohort.
| 18–60 years | >60 years | |||
| 7.5 μg HA n = 151 | 15 μg HA n = 151 | 7.5 μg HA n = 84 | 15 μg HA n = 80 | |
| Baseline | ||||
| GMT | 11 (10−12) | 11 (10−12) | 18 (14−22) | 16 (13−20) |
| MN ≥1∶40, % | 3 (1−7) | 3 (1−7) | 18 (10−28) | 15 (8−25) |
| 3 weeks after first vaccination | ||||
| GMT | 26 (22−32) | 35 (29−42) | 42 (31−59) | 51 (37–71) |
| MN ≥1∶40, % | 33 (26−41) | 44 (36−52) | 49 (38−60) | 51 (40−63) |
| 3 weeks after second vaccination | ||||
| GMT | 117 (98−140) | 102 (85−122) | 80 (61−105) | 90 (68−119) |
| MN ≥1∶40, % | 85 (78−90) | 81 (74−87) | 79 (68−87) | 76 (65−85) |
| Pre-booster (subset) | n = 71 | n = 83 | n = 38 | n = 26 |
| GMT | 33 (26−42) | 43 (34−54) | 31 (20−47) | 63 (39−101) |
| MN ≥1∶40, % | 41 (29−53) | 53 (42−64) | 42 (26−59) | 69 (48−86) |
| 3 weeks post-booster | ||||
| GMT | 210 (168−262) | 214 (174−263) | 154 (105−227) | 225 (146−345) |
| MN ≥1∶40, % | 94 (86−98) | 96 (90−99) | 97 (86−100) | 96 (80−100) |
| 6 months post-booster | n = 69 | n = 76 | n = 35 | n = 22 |
| GMT | 34 (26−44) | 35 (27−44) | 25 (17−39) | 46 (28−75) |
| MN ≥1∶40, % | 41 (29−53) | 46 (35−58) | 37 (21−55) | 64 (41−83) |
Numbers in parenthesis are two-sided 95% confidence intervals; HA, hemagglutinin; GMT, geometric mean titer